検索
Transcode Therapeutics Inc
RNAZウォッチリストに追加
7.650USD
+1.440+23.19%
終値 07/01, 16:00（ET）15分遅れの株価
7.01M時価総額
損失額直近12ヶ月PER
詳細情報 Transcode Therapeutics Inc 企業名
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Incの企業情報
企業コードRNAZ
会社名Transcode Therapeutics Inc
上場日Apr 28, 2021
最高経営責任者「CEO」Calais (Philippe P)
従業員数7
証券種類Ordinary Share
決算期末Apr 28
本社所在地6 Liberty Square
都市BOSTON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02109
電話番号18573016857
ウェブサイトhttps://www.transcodetherapeutics.com/
企業コードRNAZ
上場日Apr 28, 2021
最高経営責任者「CEO」Calais (Philippe P)
Transcode Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
よくある質問
Transcode Therapeutics Incの上位5名の株主は誰ですか？
Transcode Therapeutics Incの上位5名の株主は以下のとおりです。Mr. Thomas A. (Tom) Fitzgerald
Transcode Therapeutics Inc（RNAZ）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Transcode Therapeutics Incの株式を保有している機関は37社あり、保有株式の総市場価値は約77.85Kで、全体の8.49%を占めています。2025Q4と比較して、機関の持ち株は-42306.00増加しています。